OP Asset Management Ltd Acquires Shares of 14,139 Regeneron Pharmaceuticals, Inc. $REGN

OP Asset Management Ltd bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 14,139 shares of the biopharmaceutical company’s stock, valued at approximately $10,924,000.

Several other large investors have also made changes to their positions in REGN. WPG Advisers LLC raised its stake in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.5%

REGN stock opened at $620.14 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $514.79 and a twelve month high of $821.11. The company has a market cap of $65.56 billion, a P/E ratio of 15.11, a PEG ratio of 1.37 and a beta of 0.25. The business has a fifty day moving average of $665.93 and a 200-day moving average of $729.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the business earned $8.22 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Canaccord Genuity Group reduced their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Royal Bank Of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Finally, BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.